The FY2025 (Dec) proxy of aTYR Pharma names 16 peer companies for pay. Among aTYR Pharma and these peers, CEO pay was the lowest of 5 and total shareholder return was 4th highest of 5.
5th highest of 5in aTYR Pharma and its pay peers, FY2025 (Dec) by CEO pay:
$3.5M$33.3M
4th highest of 5in aTYR Pharma and its pay peers, FY2025 (Dec) by total shareholder return:
$22$649
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Altimmune | ||
| Savara | ||
| Trevi Therapeutics | ||
| Acelyrin, Inc. | Not disclosed | Not disclosed |
| Alector, Inc. | Not disclosed | Not disclosed |
| Allakos Inc. | Not disclosed | Not disclosed |
| Fortress Biotech, Inc. | Not disclosed | Not disclosed |
| Gossamer Bio, Inc. | Not disclosed | Not disclosed |
| Immunic, Inc. | Not disclosed | Not disclosed |
| Jasper Therapeutics, Inc. | Not disclosed | Not disclosed |
| KalVista Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Kezar Life Sciences, Inc. | Not disclosed | Not disclosed |
| Longboard Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Pliant Therapeutics, Inc. | Not disclosed | Not disclosed |
| X4 Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
16 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.